Business Context and Reporting Period
This Form 8-K Current Report was filed by Genprex, Inc. on February 12, 2019. The filing reports a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
The primary material change reported is the appointment of John N. Bonfiglio, PhD, to the Board of Directors to fill a vacancy. Dr. Bonfiglio was assigned to Class III of the Board, serving until the 2020 annual meeting of stockholders. He was appointed to the audit, compensation, and nominating and corporate governance committees.
Compensation and Governance Details
In accordance with the Company's Outside Director Compensation Policy, Dr. Bonfiglio was granted an option to purchase 45,976 shares of common stock on February 12, 2019. The exercise price is $1.45 per share, matching the closing price on the grant date. The option vests 100% upon the earlier of the one-year anniversary of the grant date or the day prior to the next annual meeting, contingent on continued service.
Investor Verification Checklist
- Verify the biographical background and qualifications of John N. Bonfiglio, PhD.
- Confirm the total number of outstanding stock options and the dilution impact of the 45,976 new shares.
- Review the press release filed as Exhibit 99.1 for additional context on the appointment.
- Check subsequent filings for any changes to the Board composition or committee assignments.